tyrosine kinase inhibitors (Cell Therapeutics)

N/A

Report date: 2025/03/20 20:00:06

Base Information

Drug Nametyrosine kinase inhibitors (Cell Therapeutics)
Drug Alias Nameoncogene pathway inhibitors (Novuspharma)c-kit inhibitors (Novuspharma)cancer drug screening (Novuspharma)ret inhibitors (Novuspharma)tyrosine kinase inhibitors (Novuspharma)
ClassificationBiologics
Mechanisms of ActionTyrosine-protein kinase receptor RET inhibitorsStem cell growth factor receptor inhibitors
TargetsTyrosine-protein kinase receptor RETStem cell growth factor receptor
Therapy Area/IndicationsNeoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryItaly
CombinationsNo
Global Highest StatusPending (Preclinical)
Highest Status in ChinaN/A
Originator CompaniesNovuspharma SpA
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesNovuspharma SpACti Biopharma Corp
Active IndicationsN/A
Inactive IndicationsNeoplasms

Other Information

ATC CodeN/A
Related LinksN/A